TARRYTOWN, N.Y.--(BUSINESS WIRE)--June 8, 2007--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentations at two investor conferences on Tuesday, June 12, 2007 and Thursday, June 14, 2007. Senior officers from Regeneron will be speaking at the Goldman Sachs Global Healthcare Conference in Dana Point, CA and at the Needham Biotechnology and Medical Technology Conference in New York, NY.
Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, will provide an overview of the Company and its clinical programs at the Goldman Sachs conference. This presentation is scheduled to be broadcast live on Tuesday, June 12, 2007 at 1:25 pm (Eastern Time). During the presentation, Dr. Schleifer will answer questions from Goldman Sachs research analysts and from the audience.
Murray A. Goldberg, Senior Vice President, Finance and Administration, and Chief Financial Officer of Regeneron, will provide an overview of Regeneron and its clinical programs at the Needham conference. This presentation is scheduled to be broadcast live on Thursday, June 14, 2007 at 2:00 pm (Eastern Time).
These two sessions may be accessed through the Company's website (www.regeneron.com on the Events page, under the Investor heading) at the time of the presentation. Archived versions of both presentations will be available, after the live webcasts, until July 13, 2007.
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.
Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com
CONTACT: Regeneron Pharmaceuticals, Inc. Charles Poole, 914-345-7640 Vice President, Investor Relations firstname.lastname@example.org or Laura Lindsay, 914-345-7678 Corporate Communications email@example.com SOURCE: Regeneron Pharmaceuticals, Inc.